


Notes: 1) The above results were reveiwed by Audit committee and approved by the Board of Directors' meeting held on 10th August 2016
2) Corresponding Previous period figures have been regrouped / reclassified whenever necessary.
3) The statutory auditors has reviewed the financial results for the quarter ended 30th June 2016. The financial results for the quarter ended 30th June 2015, 31st March 2016 \& year ended 31st March 2016 are not subject to review or audit.
4) Reconciliation between financial results previously reported (referred to as "Previous GAAP") and Ind AS for the Quarters/Year presented as under.

|  | Quarter ended |  | Year ended |
| :---: | :---: | :---: | :---: |
|  | 31/03/2016 | 30/06/2015 | 31/03/2016 |
| Net profit under previous GAAP (After Tax) | 3,229.11 | 2,023.07 | 9,496.98 |
| QIP issue expenses considered for grossing up to share premium account | 484.68 | 30.29 | 484.68 |
| Transitional effect on account of fair valuation of govt loans and reclassification of acturial loss on employee benift | 9.43 | 12.83 | 50.13 |
| Deferred tax aset due to fair valuation of Mutual funds $\mathbb{\&}$ actuarial loss on employee benefits | (5.42) | (5.99) | (23.80) |
| Net profit under Ind AS (After Tax) | 3,717.80 | 2,060.20 | 10,007.99 |
| Other Comprehensive Income | (11.30) | (11.30) | (45.22) |
| Total Comprehensive Income Under Ind AS | 3,706.50 | 2,048.90 | 9,962.77 |

For SUVEN LIFE SCIENCES LTD

Place : Hyderabad
Date: 10th August 2016

VENKAT JASTI
Chairman \& CEO
DIN: 00278028

